These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


194 related items for PubMed ID: 31044428

  • 1. HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.
    Frezzato F, Raggi F, Martini V, Severin F, Trimarco V, Visentin A, Scomazzon E, Accordi B, Bresolin S, Piazza F, Facco M, Basso G, Semenzato G, Trentin L.
    Int J Cancer; 2019 Dec 01; 145(11):3089-3100. PubMed ID: 31044428
    [Abstract] [Full Text] [Related]

  • 2. Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70.
    Banerjee Mustafi S, Chakraborty PK, Raha S.
    PLoS One; 2010 Jan 14; 5(1):e8719. PubMed ID: 20090934
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The natural compound cantharidin induces cancer cell death through inhibition of heat shock protein 70 (HSP70) and Bcl-2-associated athanogene domain 3 (BAG3) expression by blocking heat shock factor 1 (HSF1) binding to promoters.
    Kim JA, Kim Y, Kwon BM, Han DC.
    J Biol Chem; 2013 Oct 04; 288(40):28713-26. PubMed ID: 23983126
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Uric Acid-Induced Enhancements of Kv1.5 Protein Expression and Channel Activity via the Akt-HSF1-Hsp70 Pathway in HL-1 Atrial Myocytes.
    Taufiq F, Maharani N, Li P, Kurata Y, Ikeda N, Kuwabara M, Otani N, Miake J, Hasegawa A, Tsuneto M, Shirayoshi Y, Ninomiya H, Saitoh T, Nakai A, Yamamoto K, Hisatome I.
    Circ J; 2019 Mar 25; 83(4):718-726. PubMed ID: 30787218
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The long noncoding RNA NEAT1 and nuclear paraspeckles are up-regulated by the transcription factor HSF1 in the heat shock response.
    Lellahi SM, Rosenlund IA, Hedberg A, Kiær LT, Mikkola I, Knutsen E, Perander M.
    J Biol Chem; 2018 Dec 07; 293(49):18965-18976. PubMed ID: 30305397
    [Abstract] [Full Text] [Related]

  • 11. Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia.
    Ishikawa C, Mori N.
    Med Oncol; 2023 May 10; 40(6):172. PubMed ID: 37165174
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia.
    Ganguly S, Home T, Yacoub A, Kambhampati S, Shi H, Dandawate P, Padhye S, Saluja AK, McGuirk J, Rao R.
    Oncotarget; 2015 Oct 13; 6(31):31767-79. PubMed ID: 26397138
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Human esophageal microvascular endothelial cells respond to acidic pH stress by PI3K/AKT and p38 MAPK-regulated induction of Hsp70 and Hsp27.
    Rafiee P, Theriot ME, Nelson VM, Heidemann J, Kanaa Y, Horowitz SA, Rogaczewski A, Johnson CP, Ali I, Shaker R, Binion DG.
    Am J Physiol Cell Physiol; 2006 Nov 13; 291(5):C931-45. PubMed ID: 16790501
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. AKT-pathway inhibition in chronic lymphocytic leukemia reveals response relationships defined by TCL1.
    Schrader A, Popal W, Lilienthal N, Crispatzu G, Mayer P, Jones D, Hallek M, Herling M.
    Curr Cancer Drug Targets; 2014 Nov 13; 14(8):700-12. PubMed ID: 25348018
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 10.